WU, XIAODAN
 Distribuzione geografica
Continente #
EU - Europa 102
AS - Asia 82
NA - Nord America 56
AF - Africa 8
SA - Sud America 5
Totale 253
Nazione #
US - Stati Uniti d'America 56
SG - Singapore 22
GB - Regno Unito 21
DE - Germania 20
CN - Cina 18
IT - Italia 18
TR - Turchia 12
IE - Irlanda 7
RU - Federazione Russa 7
BD - Bangladesh 6
IN - India 6
IR - Iran 6
FR - Francia 5
UA - Ucraina 5
BR - Brasile 4
SE - Svezia 4
HK - Hong Kong 3
VN - Vietnam 3
EG - Egitto 2
EU - Europa 2
KR - Corea 2
MU - Mauritius 2
NG - Nigeria 2
NL - Olanda 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
ZW - Zimbabwe 2
AT - Austria 1
BA - Bosnia-Erzegovina 1
CO - Colombia 1
ES - Italia 1
FI - Finlandia 1
LB - Libano 1
MD - Moldavia 1
PH - Filippine 1
PL - Polonia 1
SI - Slovenia 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 255
Città #
Southend 15
Singapore 14
Dublin 7
Ankara 4
Ashburn 4
Beijing 4
Cagliari 4
Torrance 4
Hong Kong 3
Kiev 3
Lehi 3
Manchester 3
Milan 3
Mountain View 3
Princeton 3
San Jose 3
Seattle 3
Tianjin 3
Ahnsen 2
Antalya 2
Belgrade 2
Bucharest 2
Bursa 2
Cornate D'adda 2
Council Bluffs 2
Dhaka 2
Ho Chi Minh City 2
Jinan 2
Kermanshah 2
Los Angeles 2
Redwood City 2
Rockville 2
San Mateo 2
Somerville 2
Taizhou 2
Woodbridge 2
Zhengzhou 2
Abaetetuba 1
Alpharetta 1
Andover 1
Banja Luka 1
Barañáin 1
Bogotá 1
Brasília 1
Brest 1
Brooklyn 1
Cairo 1
Cambridge 1
Carcavelos 1
Chisinau 1
Curitiba 1
Dallas 1
Delhi 1
Des Moines 1
Egham 1
Eitensheim 1
Geisenheim 1
Goose Creek 1
Gubbio 1
Houston 1
Kharkov 1
Kumar 1
Laguna Niguel 1
Lauterbourg 1
Lisbon 1
Ljubljana 1
Medford 1
Miano 1
Moscow 1
Nanjing 1
New Delhi 1
New York 1
Odernheim 1
Perris 1
Redmond 1
Rio de Janeiro 1
Sakarya 1
Santa Clara 1
Seoul 1
Serra 1
Shenzhen 1
Tabriz 1
Tashkent 1
Terre Rouge 1
Tujunga 1
Turin 1
Valenzuela 1
Vienna 1
Wilmington 1
Totale 176
Nome #
THE ENFORCEMENT OF JUDGEMENTS IN INTERNATIONAL HUMAN RIGHTS COURT 260
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial 10
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease 1
Totale 271
Categoria #
all - tutte 496
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 496


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202220 1 2 5 1 1 0 3 0 1 1 2 3
2022/202314 2 1 1 0 2 7 0 0 1 0 0 0
2023/202410 0 0 0 0 3 0 0 5 0 1 1 0
2024/202519 0 4 1 0 1 5 0 2 1 0 0 5
2025/202661 0 1 6 6 9 3 3 6 6 7 11 3
Totale 271